72351-33-8
Chemical Structure
2-5A TEA
Synonym(s): 2′,5′-ApApA TEA; 2′,5′-trioligoadenylate TEA; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine TEA
- CAS No.: 72351-33-8
- Formula:C30H40N15O25P5·xC6H15N
- Molecular Weight:1165.59 (free base)
SMILES: CCN(CC)CC.NC1=NC=NC2=C1N=CN2[C@H]3[C@H](OP(O)(OC[C@@H](O[C@H]([C@@H]4OP(O)(OC[C@@H](O[C@H]([C@@H]5O)N6C=NC7=C6N=CN=C7N)[C@H]5O)=O)N8C=NC9=C8N=CN=C9N)[C@H]4O)=O)[C@H](O)[C@@H](COP(OP(OP(O)(O)=O)(O)=O)(O)=O)O3.[x]
Biological Activity: 2-5A TEA (2′,5′-ApApA TEA) is a 5'-triphosphorylated (2',5') oligoadenylate. When covalently linked to an antisense molecule complementary to the target sequence, 2-5A TEA activates RNase L, which subsequently degrades the target RNA bound to the 2-5A TEA chimera. 2-5A TEA can be used in research related to respiratory syncytial virus infection, colorectal adenocarcinoma and melanoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
2-5A TEA | 2-5A TEA (2′,5′-ApApA TEA) is a 5'-triphosphorylated (2',5') oligoadenylate. When covalently linked to an antisense molecule complementary to the target sequence, 2-5A TEA activates RNase L, which subsequently degrades the target RNA bound to the 2-5A TEA chimera. 2-5A TEA can be used in research related to respiratory syncytial virus infection, colorectal adenocarcinoma and melanoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Barnard DL, et al. 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral research. 1999 Apr;41(3):119-34. [Content Brief]
- [2]. Wang S, et al. 2-5A is an immunotransmitter that fuels RNase L immunity. Immunity. 2025 Apr 08;58(4):770-772. [Content Brief]
- [3]. Huai W, et al. OAS cross-activates RNase L intercellularly through cell-to-cell transfer of 2-5A to spread innate immunity. Immunity. 2025 Apr 08;58(4):797-810.e6. [Content Brief]
Keywords